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ABSTRACT: Background: Progressive supranuclear
palsy (PSP) is a neurodegenerative disorder character-
ized by neuronal loss in the extrapyramidal system with
pathologic accumulation of tau in neurons and glia. The
most common clinical presentation of PSP, referred to as
Richardson syndrome, is that of atypical parkinsonism
with vertical gaze palsy, axial rigidity, and frequent falls.
Although cognitive deficits in PSP are often ascribed to
subcortical dysfunction, a subset of patients has demen-
tia with behavioral features similar to the behavioral vari-
ant of frontotemporal dementia. In this study we aimed
to identify the clinical and pathological characteristics of
PSP presenting with frontotemporal dementia.
Methods: In this study, we compared clinical and patho-
logic characteristics of 31 patients with PSP with Richardson
syndrome with 15 patients with PSP with frontotemporal
dementia. For pathological analysis, we used semiquanti-
tative methods to assess neuronal and glial lesions with
tau immunohistochemistry, as well image analysis of tau
burden using digital microscopic methods.
Results: We found greater frontal and temporal
neocortical neuronal tau pathology in PSP with
frontotemporal dementia compared with PSP with
Richardson syndrome. White matter tau pathology
was also greater in PSP with frontotemporal dementia
than PSP with Richardson syndrome. Genetic and
demographic factors were not associated with atypical
distribution of tau pathology in PSP with frontotemporal
dementia.
Conclusions: The results confirm the subset of cognitive-
predominant PSP mimicking frontotemporal dementia in
PSP. PSP with frontotemporal dementia has distinct clini-
cal features that differ from PSP with Richardson syn-
drome, as well as differences in distribution and density of
tau pathology. © 2019 The Authors. Movement Disorders
published by Wiley Periodicals, Inc. on behalf of Interna-
tional Parkinson and Movement Disorder Society.
Key Words: behavioral variant frontotemporal demen-
tia; immunohistochemistry, image analysis; progressive
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Progressive supranuclear palsy (PSP) is a distinctive clini-
copathologic disorder characterized by accumulation of
insoluble microtubule-associated tau protein enriched in
the 4-repeat isoform.1 Tau pathology is found in vulnera-
ble regions of the neocortex and subcortical structures,
and it takes the form of neurofibrillary tangles and
pretangles in neurons, coiled bodies in oligodendrog-
lia, and tufts in astrocytes (“tufted astrocytes”).1 The
most common clinical presentation of PSP is akinetic-rigid
parkinsonism with vertical gaze palsy, axial rigidity, and
frequent falls, referred to as Richardson syndrome (PSP-
RS).2 Atypical presentations of PSP are increasingly recog-
nized, including parkinsonism (PSP-P), pure akinesia with
gait failure (PSP-PAGF), progressive nonfluent aphasia,
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and corticobasal syndrome (PSP-CBS).1 The latter 2 are
associated with disproportionate neocortical involve-
ment. Less frequently, PSP can present with clinical fea-
tures similar to the behavioral variant frontotemporal
dementia (PSP-FTD).3-5 Although a number of studies
have reported the correlation between the clinical pheno-
type and the distribution and severity of tau pathology in
PSP-RS, PSP-P, PSP-CBS, and PSP-PAGF,2,6-8 given the
rarity of PSP-FTD, there are few neuropathologic studies;
most of the current literature includes case reports or
small case series. Hassan and coworkers reported
3 patients with PSP-FTD who had initial behavioral
abnormalities, followed years later with motor symptoms
suggestive of PSP.4 Respondek and coworkers described
12 patients with clinical features of FTD in a multicenter
study of 100 autopsy-confirmed PSP patients, but did not
include details on the nature or distribution of tau pathol-
ogy.5 Because the main clinical phenotype of FTD is
behavioral change, we hypothesized that frontotemporal
pathology would correlate with these symptoms. There-
fore, we selected superior and middle frontal gyri and the
inferior temporal gyrus as regions of interest. In the pre-
sent study, we documented clinicopathological character-
istics of PSP-FTD compared with PSP-RS and
systematically assessed tau pathology in neocortical and
subcortical regions, with attention to distribution and den-
sity, as well as its cellular characteristics.
Materials and Methods
Case Materials
Patients with a neuropathological diagnosis of pro-
gressive supranuclear palsy were identified from the
neuropathology files of the Mayo Clinic Jacksonville
brain bank between 1998 and 2017. Brain autopsies
were obtained after consent of the next of kin or some-
one with legal authority to grant permission. Most
brains were submitted as part of the CurePSP Brain
Bank.9 The Mayo Clinic institutional review board has
determined that research on postmortem brain samples
is exempt from human subject research under HHS
45 CFR 46.101(b). Of 1229 cases with autopsy-
confirmed PSP in this period, 27 cases (2%) had promi-
nent behavioral disturbance, and 15 cases met criteria
for behavioral variant FTD (bvFTD). In 7 cases, PSP
was never raised in the differential diagnosis, and 4 of
these patients were referred to the brain bank as part of
studies on aging and dementia and had been evaluated
by behavioral neurologists (eg, FLorida Autopsied
Multi-Ethnic cohort10). Given the retrospective nature
of the study cohort, only cases with high-quality ante-
mortem medical documentation were included. To
increase stringency, all cases with PSP-FTD had a pri-
mary diagnosis or differential diagnosis of bvFTD made
by at least 2 neurologists. For comparison of
clinicopathological features, cases with PSP-RS were
selected based on quality and completeness of medical
records; 31 cases met inclusions criteria, which also
included matching for age, sex, and comorbid
Alzheimer’s-type pathology with PSP-FTD (Table 1).
Clinical information (age at death, sex, symptoms at pre-
sentation, symptoms during the course of the illness,
clinical diagnosis, disease duration, and family history)
was obtained from available medical records.
Clinical Assessment of PSP-FTD and PSP-RS
PSP-FTD cases had clinical features of FTD described
by Neary11 and were included if they had features consis-
tent with the behavioral variant of FTD (bvFTD).12 Other
frontotemporal syndromes such as progressive nonfluent
aphasia, semantic dementia, or progressive asymmetrical
rigidity and apraxia (ie, corticobasal syndrome) were
excluded. The behavioral features recorded on each case
were classified as: A, disinhibition; B, apathy; C, loss of
sympathy or empathy; D, preservative, stereotyped, or
compulsive/ritualistic behavior; and E, hyperorality and
dietary changes. For clinical diagnosis of Richardson syn-
drome, we used criteria originally reported by Williams
and coworkers, which are similar to recently published
Movement Disorder Society criteria.2,13
TABLE 1. Demographics and neuropathology of PSP-FTD
and PSP-RS
PSP-FTD PSP-RS
(n = 15) (n = 31)
Demographics
Female 3 (20%) 10 (32%)
Age at death 73 (69, 75) 75 (72, 78)
Disease duration 9 (6, 10) 7 (6, 9)
Genetics
MAPT (H1H1) 50% 73%
APOE (ε4 carrier) 33% 18%
Pathology
Brain weight 1140 (1100, 1240) 1140 (1095, 1200)
Braak NFT stage II (I-II, III) II-III (I-II, III)
Thal amyloid phase 0 (0, 3) 1 (0, 2)
Neurofibrillary tangle counts (X400), with thioflavin-S fluorescent
microscopy
Middle frontal gyrus 0 (0, 0) 0 (0, 0)
Superior temporal gyrus 0 (0, 0) 0 (0, 0)
Inferior parietal lobule 0 (0, 0) 0 (0, 0)
Hippocampus— CA4 0 (0, 1) 0 (0, 1)
Hippocampus— CA2/3 0 (0, 1) 1(0, 2)
Hippocampus— CA1 1 (0, 2) 1 (0, 2)
Hippocampus— subiculum 1(0, 2.5) 1 (0, 2)
Neuronal loss (score with hematoxylin and eosin histochemistry)
Substantia nigra 3 (2, 3) 2 (2, 3)
Locus coeruleus 3 (2.5, 3) 3 (2, 3)
Analyses used Kruskal-Wallis analysis of variance on ranks, and data are dis-
played as median (25th percentile, 75th percentile) or percent of patients with
the specific feature, unless otherwise noted. Genetic comparisons with Fisher’s
exact test. None of the variables differed significantly between the 2 groups.
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Genetic Analyses
Genotyping was performed with a TaqMan allelic Dis-
crimination Assay on an ABI 7900HT Fast Real-Time
PCR system (Applied Biosystems). One single-nucleotide
polymorphism (SNP; rs1052553) was used to determine
the MAPT haplotype, and 2 SNPs (rs7412 and
rs429358) were used to determine the APOE genotype.
Microscopic Pathology
All cases had standardized dissections, sampling, and
tissue processing, and they were all evaluated by a single
neuropathologist (D.W.D.). Formalin-fixed, paraffin-
embedded tissue samples were cut at a 5-μm thickness
and mounted on glass slides for study. In addition to
histologic evaluation, the presence and severity of
Alzheimer’s pathology was assessed with thioflavin-S
fluorescent microscopy. A Braak neurofibrillary tangle
stage14 and Thal amyloid phase15 were assigned to each
case based on lesion counts in cortical and subcortical
areas with thioflavin-S fluorescent microscopy as previ-
ously described.16
Immunohistochemistry
Immunohistochemistry was performed on 5-μm-thick
sections of formalin-fixed, paraffin embedded tissue.
Glass-mounted sections were deparaffinized in xylene
and rehydrated in ethanol and distilled water. Immuno-
histochemistry for tau used an antibody to phospho-
serine 202 (CP13; mouse monoclonal; from Peter
Davies, PhD, Feinstein Institute, North Shore Hospital,
Manhasset, NY) and for TDP-43, a rabbit polyclonal
antibody to a mid-region neoepitope (MC2085; from
Leonard Petrucelli, PhD, Mayo Clinic Jacksonville,
Jacksonville, FL). The following regions were evaluated
with digital pathology: superior frontal gyrus, middle
frontal gyrus, inferior temporal gyrus, and motor cor-
tex. Immunohistochemical preparations were processed
on a DAKO AutostainerPlus (Agilent/DAKO, Santa
Clara, CA) with a DAKO EnVision+ system–HRP with
3,30-diaminobenzidine (DAB) as the chromogen. Non-
specific antibody binding was blocked with normal goat
serum (Sigma, St. Louis, MO).
Image Analysis
Digital microscopy methods have been previously
described. Briefly, immunostained sections were scanned
on an Aperio ScanScope XT slide scanner (Aperio Tech-
nologies, Vista, CA), producing a high-resolution digital
image. Digital image analysis was performed using
Aperio ImageScope software. Several regions of interest
were outlined from each image. A color deconvolution
algorithm was used to count the number of pixels that
were immunostained by the DAB chromogen in the
manually outlined regions. The color channels for the
color deconvolution algorithm were based on the DAB
chromogen. Based on the chromogen staining density of
the digital slide image, the algorithm assigns each pixel
an intensity range, binned into strong staining (red),
moderate staining (orange), weak staining (yellow), or
no staining (blue). The signal for tau was considered
positive if the pixel was red, orange, or yellow. Areas
with no staining (white) and those below threshold (blue)
were considered negative. The output variable was per-
centage of positive pixels relative to the total area of the
region of interest.
Statistical Analysis
Sigma Plot version 12 (Systat Software, San Jose, CA)
was used for statistical analyses. Because of the small
sample sizes, nonparametric Kruskal-Wallis analysis of
variance on ranks was performed on quantitative mea-
sures to assess differences in the median values. Post hoc
pairwise comparisons were performed between each of
the groups using the Mann-Whitney rank sum test. For
categorical data (eg, sex, APOE and MAPT genotypes,
and clinical symptoms), a chi-square test was used to
compare group differences. Fisher’s exact test was used
for comparison of pairwise categorical data if the counts
were less than 5. Correlative analysis was performed
using Spearman rank order correlation. Kruskal-Wallis
rank sum tests were used for ordered categorical or con-
tinuous variables in pathogenic analyses. A statistically
significant difference was considered for a 2-sided
P < 0.05. For comparison of tau pathology between
PSP-FTD and PSP-RS, Mann-Whitney rank sum tests
were performed, and P < 0.0083 using a Bonferroni cor-
rection was considered significant.
Results
Demographics, Pathology, and Genetics
The 15 autopsy-proven PSP cases with antemortem
clinical diagnosis of bvFTD were compared with
31 cases of PSP with Richardson syndrome. By design,
PSP-FTD did not differ from PSP-RS with respect to
sex, age at death, disease duration, brain weight, Braak
neurofibrillary tangle stage, or Thal amyloid phase.
They were also similar in neurofibrillary tangle counts
with thioflavin-S fluorescent microscopy and the sever-
ity of neuronal loss assessed semiquantitatively in a
ventrolateral cell group of the substantia nigra17 and in
the locus coeruleus (Table 1). There were no differences
in frequency of MAPT H1H1 or APOE ε4 between
PSP-FTD and PSP-RS.
Clinical Comparison of PSP-FTD and PSP-RS
Clinical features of PSP-FTD and PSP-RS at presenta-
tion and later in the disease course are summarized in
Table 2. At initial presentation, only 1 patient with
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PSP-FTD had unexplained falls (6%), whereas 94% of
PSP-RS patients had early unexplained falls or signifi-
cant gait disturbance (P < 0.001). There was no differ-
ence in frequency of vertical gaze palsy or limb
dysfunction. All PSP-FTD patients had initial cognitive
or behavioral problems, including personality changes
(P < 0.001), a language disorder (P = 0.02), or memory
complaints. These features were very uncommon as an
initial complaint in PSP-RS. Disinhibition was signifi-
cantly more frequent in PSP-FTD compared with PSP-
RS (P < 0.001), and a language disorder was also more
frequent in PSP-FTD (P = 0.008). In contrast, motor
problems were universal in PSP-RS patients at presenta-
tion. Parkinsonism, gait disorder, falls, and vertical
gaze palsy were significantly more frequent during the
disease course in PSP-RS compared with PSP-FTD.
Although all PSP-FTD cases were considered to have
FTD, more than half of the PSP-FTD patients also had
mild motor problems, such as falls, gait problems, or
parkinsonism (Table 2).
Pathological Findings
Disproportionate atrophy was observed in the frontal
lobe was noted. Pigment loss in the substantia nigra was
not obvious, and the superior cerebellar peduncle had
no significant atrophy in PSP-FTD (Fig. 1A–C). Tau
pathology was assessed in PSP-FTD and PSP-RS with
phospho-tau immunohistochemistry (Fig. 1D–G). Digital
microscopy image analysis was used to quantify the den-
sity of phospho-tau pathology (Fig. 2). In the superior
frontal gyrus, PSP-FTD patientshad significantly greater
phospho-tau burden compared with PSP-RS (P = 0.008).
PSP-FTD patients also had greater tau pathology in the
white matter of the superior frontal gyrus (P = 0.08),
middle frontal gyrus (P = 0.07), and inferior temporal
gyrus, reaching statistical significance in the inferior tem-
poral gyrus (P = 0.001); see Table 3. These results sug-
gest that tau density and distribution might be associated
with behavioral features in PSP-FTD.
We also evaluated the nature of tau pathologies,
focusing on neuronal pathology (neurofibrillary tangles
[NFTs] and pretangles), neuropil threads, and glial
lesions (tufted astrocytes and oligodendroglial coiled
bodies). Neuronal tau pathology was significantly
greater in the superior frontal gyrus and inferior tempo-
ral gyrus of PSP-FTD compared with PSP-RS (Table 3).
Neuropil threads were abundant in both PSP-FTD and
PSP-RS, with significantly more threads in the superior
frontal gyrus and motor cortex in PSP-FTD compared
with PSP-RS (Table 3). Tufted astrocytes did not differ
between PSP-FTD and PSP-RS (not shown). Oligoden-
droglial coiled bodies were more numerous in the supe-
rior frontal gyrus and middle frontal gyrus of PSP-FTD
compared with PSP-RS (Table 3). These results suggest
that greater neuronal and glial tau pathology in both
gray matter and white matter of the frontal and tempo-
ral lobes is associated with PSP-FTD.
Discussion
PSP-RS is a distinctive disorder with high diagnostic
accuracy confirmed by postmortem neuropathologic
studies.9 Early clinical manifestations of PSP-RS are
related to motor problems, with frequent falls and verti-
cal gaze palsy18; however, many patients also develop
cognitive dysfunction that has characteristics of a sub-
cortical dementia, characterized by cognitive dysfunc-
tion, bradyphrenia, slow responses, and poor recall.19
A subset of PSP patients has more marked cognitive
deficits and features that mimic bvFTD.20,21 In this
study, we aimed to better understand clinical and path-
ologic features of PSP-FTD. In the Mayo Clinic brain
bank for neurodegenerative disorders, we identified
15 patients with pathologically confirmed PSP and
antemortem clinical features of bvFTD (PSP-FTD).
Only 1 patient had early unexplained falls typical of
PSP-RS, whereas the remaining patients had cognitive
and behavioral features that overshadowed motor fea-
tures. Most of the PSP-FTD patients developed motor
dysfunction during the disease course, but 4 patients
never had significant motor problems. These 4 patients
were thought to have bvFTD as the final diagnosis
TABLE 2. Comparison of clinical features of PSP-FTD and
PSP-RS
PSP-FTD PSP-RS
P(n = 15) (n = 31)
Initial presentation
Motor dysfunction
Parkinsonism 0 (0%) 4 (13%)
Gait disorder and falls 1 (6%) 29 (94%) <0.001
Vertical gaze palsy 0 (0%) 2 (6%)
Limb dysfunction 0 (0%) 2 (6%)
Cognitive impairment
Personality or behavioral changes 10 (67%) 2 (6%) <0.001
Language disorder 4 (27%) 1 (3%) 0.02
Memory problems 4 (24%) 2 (6%)
Features during disease course
Motor dysfunction
Parkinsonism 2 (12%) 31 (100%) <0.001
Gait disorder and falls 8 (53%) 31 (100%) <0.001
Dystonia 0 1 (3%)
Vertical gaze palsy 5 (33%) 31 (100%) <0.001
Cognitive impairment
Disinhibition 10 (67%) 3 (9%) <0.001
Apathy or abulia 6 (40%) 5 (15%)
Memory problems 3 (20%) 6 (18%)
Language disorder 7 (41%) 3 (10%) 0.008
Limb apraxia 1 (7%) 2 (6%)
Visuospatial disorder 2 (14%) 5 (16%)
Data are displayed as frequency of a given clinical feature (percent of total in
that group). Post hoc pairwise comparison analysis was performed with
Mann-Whitney rank sum test. Only statistically significant P values are shown.
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before death. All PSP-FTD patients had features consis-
tent with bvFTD. The most common behavioral prob-
lem was that of disinhibition. Abulic or apathetic
features are common in subcortical dementia,19 but like
our series, Gerstenecker and coworkers also reported
that only 8% of a series of 154 clinically diagnosed PSP
patients had moderate to severe apathy, whereas disin-
hibition was present in 21%.22
Clinical features are known to overlap and to evolve
with disease progression in individuals with frontotemporal
degenerative disorders.23 In a series of 60 autopsy-
confirmed cases of frontotemporal degeneration studied
by Kertesz and coworkers, more than half (n = 32) pres-
ented with bvFTD. In none of the cases was PSP found
at autopsy. The most common tauopathies associated
with bvFTD were corticobasal degeneration and Pick’s
disease.23 Review of the literature would also suggest
that bvFTD is an uncommon presentation of PSP. In a
study of 66 autopsy-confirmed cases of PSP by Hassan
and coworkers, only 3 cases of 66 PSP patients (4%)
presented with behavioral and personality changes consis-
tent with bvFTD.4 A retrospective multicenter European
study of autopsy-confirmed (“definite”) PSP showed the
frequency of FTD-like features in 12 of 100 cases.5 In
that series, 7 patients had both progressive nonfluent
aphasia and bvFTD, whereas 4 had only bvFTD. Bigio
and coworkers studied tau pathology in the frontal neo-
cortex (both gray matter and white matter) of a series of
typical PSP patients and PSP patients with dementia. The
dementia characteristics were not specifically those of
bvFTD, but rather Alzheimer’s-type dementia with or
without parkinsonism, hydrocephalus, Binswanger’s dis-
ease, or corticobasal syndrome. Like the current study,
they found increased cortical tau pathology in PSP with
dementia compared with PSP without dementia.24 In
that series, most patients presented with attention and
FIG. 1. Macroscopic and phospho-tau immunohistochemistry in PSP-FTD. Cerebral atrophy is marked in frontal cortex (A). Pigmentation of substantia
nigra is preserved (B).The superior cerebellar peduncle has no atrophy (C). Representative phospho-tau immunohistochemistry of superior frontal cor-
tex in PSP. Phospho-tau pathology is present in both gray matter and white matter in PSP-FTD and PSP-RS. In gray matter, NFTs (D), threads (E), and
tufted astrocytes (F) are illustrated, whereas coiled bodies are seen in the white matter (G). Scale bar: 20 μm
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memory deficits, with fewer showing language problems;
only 2 patients had early behavioral problems.24
Although these previous studies had investigated the
neuropathology of PSP with dementia, the current study
is the first to focus exclusively on patients meeting clini-
cal criteria for bvFTD.
A more significant body of literature has characterized
neuroimaging features of PSP presenting with frontal
FIG. 2. Image analysis of phospho-tau in PSP-FTD and PSP-RS. Representative images of phospho-tau immunohistochemistry in superior frontal cortex
of PSP. Phospho-tau pathology is present in both gray matter and white matter in PSP-FTD (A), but much less in PSP-RS (B). Tufted astrocytes are more
frequent in PSP-FTD than PSP-RS (arrow). Dashed line indicates junction between gray matter and white matter. Scale bar: 200 μm. Digital image analysis
of phospho-tau immunohistochemistry in the superior frontal cortex of PSP-FTD (C) and PSP-RS (D). Higher magnification image of PSP-FTD (E, G) and
higher magnification image of digital analysis of PSP-FTD (F, H). Application of the image analysis color deconvolution algorithm shows strong positive
pixels as red. A positive pixel count algorithm was customized to quantify immunoreactive pixels (red), subtracting inverse pixels (blue), and background
pixels (yellow). The analysis does not discriminate between NFTs, neuropil threads, coiled bodies, and tufted astrocytes. Dashed line indicates junction of
gray matter and white matter. Scale bar: 150 μm (A–D). Scale bar: 30 μm (E–H).
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executive and behavioral dysfunction.25-27 Cordato and
coworkers correlated behavioral changes in PSP with
atrophy in the orbitofrontal cortex and the midbrain.26
Using voxel-based morphometry, Josephs and coworkers
reported that behavioral changes in PSP correlated with
frontostriatal volume loss.25 Chiu and coworkers, com-
paring 21 patients with PSP-RS with 11 patients with
PSP-FTD, reported that frontobehavioral features in PSP
were associated with hypoperfusion in the posterior part
of the cingulate gyrus and that hypoperfusion correlated
with the severity of executive dysfunction.28 The neuro-
pathologic basis for these neuroimaging observations
was not reported. In the present study, we found that
PSP-FTD had significantly greater total tau burden in the
superior frontal gyrus in both cortical gray matter and
subcortical white matter, as well as greater white matter
tau pathology in middle frontal and inferior temporal
gyri. The lesion types most likely to account for this
increased burden were pretangles and neuropil threads,
but oligodendroglial coiled bodies were also increased in
PSP-FTD compared with PSP-RS. Our results provide
evidence that not only total tau burden, but also neuro-
nal and oligodendroglial tau pathology is associated with
bvFTD presentation of PSP.
Regarding white matter pathology in PSP and specifi-
cally in PSP-FTD, genome-wide association studies of
PSP and CBD identified a variant near MOBP, a myelin
oligodendrocyte protein.29,30 It is of note that neuroimag-
ing studies have suggested that white-matter abnormali-
ties may correlate with apathy and impulsivity in PSP.31
Caso and coworkers reported that white-matter damage
showed significant correlation with cognitive features in
PSP-RS, but regional cortical thinning did not.32 In this
study, we observed significantly greater density of tau
pathology in both gray and white matter of PSP-FTD.
The present study has strengths and limitations. Neu-
ropathologic characterization is a strength, in that all
cases were referred to a single brain bank, and neuro-
pathologic procedures were standardized. The analyses
included both semiquantitative lesion burden scores
and tau burden using digital pathology and image anal-
ysis in regions of interest. A weakness is that the PSP
cases were a sample of convenience and were not neces-
sarily representative of a population-based cohort.
Patients with atypical clinical presentations may dispro-
portionately come to autopsy,33 which might imply that
the bvFTD subtype of PSP may be even less frequent
than that observed (ie, less than 2%). Another weak-
ness is that medical documentation was variable and
not standardized; however, only cases with high-quality
medical documentation and confirmation of the diagno-
sis by 2 neurologists were included in the final analyses.
In conclusion, we found that PSP-FTD represents an
uncommon clinical subtype of PSP, with disinhibition
more frequent than apathy/abulia. PSP-FTD differs
from PSP-RS by greater tau pathology in the gray and
white matter of the superior frontal gyrus, middle fron-
tal gyrus, and inferior temporal gyrus. PSP-FTD does
not differ from PSP-RS with respect to common genetic
risk factors (eg, APOE and MAPT). Further studies are
warranted to understand the factors that contribute to
this unusual presentation of PSP.
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Superior frontal gyrus 0.6 (0.3, 1.2) 0.3 (0.15, 0.49) 0.008
Middle frontal gyrus 0.3 (0.2, 0.4) 0.2 (0.08, 0.49)
Inferior temporal gyrus 0.1 (0.1, 0.4) 0.1 (0.0, 0.2)
Subcortical white mater
Superior frontal gyrus 0.4 (0.2, 0.8) 0.2 (0.1, 0.4)
Middle frontal gyrus 0.2 (0.1, 0.4) 0.1 (0.08, 0.3)
Inferior temporal gyrus 0.1 (0.1, 0.3) 0.04 (0.0, 0.1) 0.001
All variables were analyzed with Kruskal-Wallis analysis of variance on ranks,
and data are displayed as median (25th percentile, 75th percentile), unless
otherwise noted. Post hoc pairwise comparison analysis was performed with
Mann-Whitney rank sum test. Only statistically significant P values are
shown. Corpus callosum thickness measures are in centimeters.
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